Next 10 |
2024-07-12 14:30:06 ET More on Exact Sciences: Exact Sciences: Still No Reason To Own Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript Exact Sciences initiated at sector outperform at Scotiabank on advanced diagnostics Exact Sciences gains a...
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...
2024-07-03 07:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare . In 2024, the market ...
2024-06-27 17:29:05 ET More on Exact Sciences Exact Sciences: Still No Reason To Own Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences gains as TD Cowen sees 25%...
2024-06-26 18:30:02 ET Scotiabank analyst issues OUTPERFORM recommendation for EXAS on June 26, 2024 04:27PM ET. EXAS was trading at $44.16 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Strong Buy, ...
2024-06-26 18:00:04 ET Sung Ji Nam from Scotiabank issued a price target of $70.00 for EXAS on 2024-06-26 16:27:00. The adjusted price target was set to $70.00. At the time of the announcement, EXAS was trading at $44.16. The overall price target consensus is at $96.29 w...
2024-06-26 15:12:30 ET More on Exact Sciences Exact Sciences: Still No Reason To Own Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences patent infringement case a...
2024-06-26 09:15:03 ET BTIG analyst issues BUY recommendation for EXAS on June 26, 2024 07:41AM ET. The previous analyst recommendation was Buy. EXAS was trading at $41.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst re...
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...